Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taron

Showing results (281-290 of 327) with videos related to

Pageof 33
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2014
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trialCarlota Costa, Miguel Angel Molina, Ana Drozdowskyj, et al.
Journal of Translational Medicine|December 21, 2010
Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancerSara Simonetti, Miguel Angel Molina, Cristina Queralt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2007
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancerManuel Cobo, Dolores Isla, Bartomeu Massuti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 27, 2005
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patientsH Cortes-Funes, C Gomez, R Rosell, et al.
Clinical Proteomics|June 15, 2024
Glial fibrillary acidic protein, neurofilament light, matrix metalloprotease 3 and fatty acid binding protein 4 as non-invasive brain tumor biomarkersAtefeh Ghorbani, Miyo K Chatanaka, Lisa M Avery, et al.
Plos One|March 4, 2014
Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trialSusana Benlloch, Maria Luisa Botero, Jordi Beltran-Alamillo, et al.
Molecular Biology and Evolution|December 24, 2016
Complex Admixture Preceded and Followed the Extinction of Wisent in the WildKarolina Wecek, Stefanie Hartmann, Johanna L A Paijmans, et al.
Clinical Lung Cancer|June 26, 2004
Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancerVicente Alberola, Carme Sarries, Rafael Rosell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)J Martin-Broto, A Redondo, C Valverde, et al.
AIDS (London, England)|July 28, 2023
Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIVJordan E Lake, Jana Taron, Heather J Ribaudo, et al.
Pageof 33

Showing results (281-290 of 327) with videos related to

Sort By:
Pageof 33
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2014
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trialCarlota Costa, Miguel Angel Molina, Ana Drozdowskyj, et al.
Journal of Translational Medicine|December 21, 2010
Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancerSara Simonetti, Miguel Angel Molina, Cristina Queralt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2007
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancerManuel Cobo, Dolores Isla, Bartomeu Massuti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 27, 2005
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patientsH Cortes-Funes, C Gomez, R Rosell, et al.
Clinical Proteomics|June 15, 2024
Glial fibrillary acidic protein, neurofilament light, matrix metalloprotease 3 and fatty acid binding protein 4 as non-invasive brain tumor biomarkersAtefeh Ghorbani, Miyo K Chatanaka, Lisa M Avery, et al.
Plos One|March 4, 2014
Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trialSusana Benlloch, Maria Luisa Botero, Jordi Beltran-Alamillo, et al.
Molecular Biology and Evolution|December 24, 2016
Complex Admixture Preceded and Followed the Extinction of Wisent in the WildKarolina Wecek, Stefanie Hartmann, Johanna L A Paijmans, et al.
Clinical Lung Cancer|June 26, 2004
Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancerVicente Alberola, Carme Sarries, Rafael Rosell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)J Martin-Broto, A Redondo, C Valverde, et al.
AIDS (London, England)|July 28, 2023
Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIVJordan E Lake, Jana Taron, Heather J Ribaudo, et al.
Pageof 33